<DOC>
	<DOCNO>NCT00318786</DOCNO>
	<brief_summary>This trial conduct Japan . This clinical trial study efficacy safety three time day BIAsp-70 compare two time day BIAsp-30 subject type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Safety Three Times Day BIAsp-70 Compared Two Times Day BIAsp-30 Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Subjects type 2 diabetes Current treatment use intermediateacting , longacting insulin ( include longacting insulin analogue ) premixed human insulin least 24 week HbA1c least 7.5 % 10.0 % Proliferative retinopathy maculopathy require acute treatment Impaired hepatic and/or renal function Cardiac diseases Uncontrolled hypertension Known hypoglycemia unawareness recurrent major hypoglycemia</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>